Letters to the Editor
Alternatives to Rehydration During Hypodermoclysis
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2002 Jul 1;66(1):28-30.
to the editor: I was glad to read “Hypodermoclysis: An Alternative Infusion Technique.”1 In palliative care settings, often rehydration is not necessary for comfort and may worsen the situation with unwanted pulmonary edema, skin edema, or ascites. In addition to fluids, the physician can also provide the patient with parenteral medications during hypodermoclysis. At the Rainey Hospice House, this technique has helped us to medicate patients who cannot swallow or whose vomiting precludes using their gastrointestinal tract, without resorting to intravenous or central lines. We find hypodermoclysis especially useful for three classes of patients.
First, we use hypodermoclysis to give parenteral opioids when patients in pain cannot get adequate relief by oral or transdermal medicines. We find that hydromorphone works best for this indication because its potency requires a very small amount of infusate to deliver high doses of analgesic. Morphine can also be administered this way, using a patient-controlled pump.
Second, in patients with severe nausea syndromes, hypodermoclysis can be used to deliver medicines such as metoclopramide (Reglan), lorazepam (Ativan), diphenhydramine (Benadryl), dexamethasone (Decadron), or promethazine (Phenergan). Some of these medicines can be combined to hit multiple brain and gut receptors that mediate nausea syndromes, but physicians must be careful of parenteral drug incompatibilities. Although little data are available on this topic, we often use a combination drip of dexamethasone, lorazepam and diphenhydramine with good nausea control in these patients. Many of these patients additionally require metoclopramide, which must be administered in a separate drip or transdermally because of incompatibility issues.
Finally, hypodermoclysis can be used for patients who require palliative sedation for uncontrolled delirium near the end of life. One can use a pump to control a drip of lorazepam, midazolam, or others to achieve the proper level of sedation to control the patient's symptoms. In severely agitated patients, one can put the infusion in the skin between the shoulder blades so that the patient cannot pull it out during their confusion.
1. Sasson M, Shvartzman P. Hypodermoclysis: an alternative infusion technique. Am Fam Physician. 2001;64:1575–8.
in reply: We would like to thank Dr. Woodall for his comments. We agree that there is controversy regarding hydration in the palliative care setting. In most cases, the worst case scenario is that it does not help. In our experience, some families find it too hard to deal with the patient not eating and drinking, and hydration through hypodermoclysis symbolically seems to answer this cultural need. Hypodermoclysis can be used in the palliative setting as well as in the geriatric population, and other adult populations in home care or in nursing settings of home care.
We also administer drugs via hypodermoclysis without the use of a pump, and our clinical impression is that it works. A literature search that we conducted found no documentation of this method; we are currently examining this issue. There is wide literature on administering drugs in a subcutaneous infusion by a pump. The following medications are included in this category: atropine (Urised), dexamethasone (Decadron), haloperidol (Haldol), hydromorphone (Dilaudid-Hp), hydroxyzine (Atarax), methadone, methotrimeprazine (Levoprome), metoclopramide (Reglan), midazolam (Versed), morphine (Duramorph), octreotide (Sandostatin), phenobarbital, promethazine (Phenergan), scopolamine (Transderm Scop).
The following medications are incompatible: ranitidine and haloperidol, midazolam and dexamethasone, haloperidol and dexamethasone, ranitidine and metoclopramide, and ranitidine and midazolam. Check with your hospital pharmacist before combining any medicines administered via infusion.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2002 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions